SOUTH SAN FRANCISCO, Calif. & SEATTLE-- (BUSINESS WIRE)--May 13, 2025-- ...

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the ...

SOUTH SAN FRANCISCO, Calif. & SEATTLE, May 13, 2025--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg ...

and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown ...

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will be sharing oral and ...

Sonoma Biotherapeutics Announces Oral and Poster Presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting Sonoma Biotherapeutics, Inc., a clinical-stage ...

Littman is a co-founder of Vendanta Biosciences and ImmunAI, and serves on the advisory boards of IMIDomics, Sonoma Biotherapeutics, NILO Therapeutics, and Evommune, and on the board of directors ...

Sparks received research support from Boehringer Ingelheim, Bristol Myers Squibb, Janssen, and Sonoma Biotherapeutics. He consulted for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb ...

US clinical-stage biotech Sonoma Biotherapeutics says it has received a $45 million milestone payment from Regeneron Pharmaceuticals (Nasdaq: REGN), under the terms of its active collaboration to ...

Sonoma Biotherapeutics on Wednesday announced that it received a $45 million payment from Regeneron Pharmaceuticals for meeting a significant milestone in its efforts to research, develop and ...